Table 2.
List and Percentage of Comorbidities Within the Study Population
| Total Population (N=164) | BEC 300–450 (N=34) | |
|---|---|---|
| ≥1 relevant comorbidity | 144 (87.8%) | 30 (88.2%) |
| ≥1 current asthma-related condition | 90 (54.9%) | 18 (52.9%) |
| Nasal polyposis | 89 (54.3%) | 19 (55.9%) |
| GERD | 40 (24.4%) | 9 (26.5%) |
| Allergic conjunctivitis | 24 (14.6%) | 4 (11.8%) |
| Allergic rhinitis | 36 (22%) | 6 (17.6%) |
| ≥1 current OCS-related condition | 60 (40.2%) | 17 (50%) |
| Hypertension | 41 (25%) | 6 (17.6%) |
| Osteoporosis | 20 (12.2%) | 7 (20.6%) |
| Cataracts | 11 (6.7%) | 5 (14.7%) |
| Anxiety/Depression | 7 (4.2%) | 4 (11.7%) |
| Type 2 diabetes mellitus | 9 (5.5%) | 2 (5.9%) |
| Obstructive sleep apnea | 8 (4.9%) | 3 (8.8%) |
| Cardiovascular disease | 7 (4.3%) | 3 (8.8%) |
| ≥1 other ongoing comorbidities | 28 (17.1%) | 7 (20.6%) |
| Thyroid disorders | 8 (4.9%) | 2 (5.9%) |
| Bronchiectasis | 6 (3.7%) | 2 (5.9%) |
Abbreviations: GERD, gastroesophageal reflux disease; OCS, oral corticosteroids; BEC, blood eosinophil count, measured in cells/mm3.